SCHEMBL6002380

SCHEMBL6002380

CCCN1CC2CC2(c2ccc(F)cc2)C1

nearest known ligand 0.65

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.48
DRD3 P35462 4/20 0.48
KCNH2 Q12809 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4073749 0.88 KCNH2 (0.51) DRD2DRD3KCNH2
SCHEMBL4074941 0.87 KCNH2 (0.43) DRD2DRD3KCNH2
Hydrochloric Acid SCHEMBL5447866 0.85 KCNH2 (0.42) DRD2DRD3KCNH2
SCHEMBL4180287 0.85 SLC6A2 (0.50) DRD2DRD3KCNH2
SCHEMBL6003533 0.85 DRD3 (0.54) DRD2DRD3KCNH2
SCHEMBL6002381 0.83 DRD2 (0.50) DRD2DRD3KCNH2
SCHEMBL4248553 0.83 DRD2 (0.48) DRD2DRD3KCNH2
SCHEMBL4178756 0.82 DRD2 (0.42) DRD2DRD3KCNH2
SCHEMBL4188483 0.82 DRD2 (0.42) DRD2DRD3KCNH2
Hydrochloric Acid SCHEMBL4183193 0.81 DRD2 (0.41) DRD2DRD3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060223875-A1 Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes DOV PHARMACEUTICAL, INC. 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223875-A1 Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes HTR1B, SLC6A3, CYP1B1 DRD2 227/4885DRD3 239/4885KCNH2 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.